Skip to content
Menu

Cellebrite DI Ltd. CLBT

Full chart Compare
Set alert

Price alert · CLBT

All alert types
10.77 USD -0.55 (-4.86%)

Regular-session close

11.23 +0.46 +4.27%

After hours · Nov 20, 4:00 PM ET

10.72 Day range 11.41
9.58 52-week range 19.39
YTD
-40.27%
1 year
-38.25%

Fundamental scorecard

15 of 25 checks passed on CLBT’s reported financials

ValueGrowthProfitabilityHealthDividend

15of 25 checks passed

  • Value 3 of 5
  • Growth 4 of 5
  • Profitability 3 of 5
  • Financial health 5 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Value 3 of 5

  • Failed:P/E below its own 5-year median P/E 41.5 against a 5-year median of 20.5.
  • Failed:P/E under 20 P/E 41.5: an earnings yield of 2.4%.
  • Passed:Price to sales below its own 5-year median Price to sales 5.0 against a 5-year median of 5.9.
  • Passed:Price to book below its own 5-year median Price to book 4.7 against a 5-year median of 12.3.
  • Passed:Free cash flow yield above 4% Free cash flow of 166M is 6.1% of the market value.

Growth 4 of 5

  • Passed:Revenue grew over the last year Revenue of 537M is +17.9% on the 12 months before.
  • Passed:Revenue grew more than 5% a year over five years +19.5% a year from FY 2020 to FY 2025.
  • Failed:Earnings per share grew over the last year EPS 0.24 against 0.38 in the 12 months before.
  • Passed:Earnings per share grew more than 5% a year over five years EPS -0.08 in FY 2020, 0.31 in FY 2025.
  • Passed:Analysts expect higher earnings per share over the next year The average forward estimate is +167.7% on the last 12 months.

Profitability 3 of 5

  • Passed:Profitable over the last year Net income of 65.2M over the last 12 months.
  • Failed:Profitable in each of the last five fiscal years A profit in 3 of the last 5 fiscal years.
  • Failed:Return on equity above 15% Return on equity of 12.7%.
  • Passed:Net margin above its 5-year average Net margin of 12.1% against a 5-year average of -1.5%.
  • Passed:Free cash flow is at least 80% of net income Free cash flow of 166M is 254.5% of net income.

Financial health 5 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 658M against short-term liabilities of 395M.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 658M against long-term liabilities of 93.7M.
  • Passed:Net debt under 40% of equity More cash than debt: 484M of cash against 23.4M of debt.
  • Passed:Operating cash flow covers at least 20% of debt Operating cash flow of 181M is 774.5% of debt.
  • Passed:Operating profit covers interest at least 3 times No interest expense reported.

Dividend No data

  • No data:Pays a dividend Not enough data to decide.
  • No data:Yield above 1.5% Not enough data to decide.
  • No data:Pays out under 75% of profit Not enough data to decide.
  • No data:Covered by free cash flow Not enough data to decide.
  • No data:Not cut in the last five fiscal years Not enough data to decide.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What CLBT owns and owes, as of Sep 30, 2026

Short term and long term

Balance sheet · 1.07B of assets

Debt, equity and cash by year

Now: 461M more cash than debt

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

4.46 Safe zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

4 / 9 Average

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

A-4 / 5 overall

  • DCF 4
  • Return on Equity 4
  • Return on Assets 4
  • Debt / Equity 4
  • P/E 2
  • P/B 2

Valuation

P/E 58.2×
P/S 9.5×
P/B 9.3×
P/FCF 28.9×
EV/EBITDA 42.7×
EV/Sales 9.3×
FCF Yield 3.5%

Profitability

Gross Margin 84.2%
Operating Margin 14.0%
Net Margin 16.5%
ROE 16.2%
ROIC 10.0%
ROA 8.3%

Growth (YoY)

Revenue 18.6%
Operating Income 16.8%
EPS (diluted) 123.0%
Free Cash Flow 28.1%

Financial Health

Current Ratio 1.6×
Quick Ratio 1.5×
Debt / Equity 0.0×
Net Debt / EBITDA -1.0×
Interest Coverage 0.0×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31